BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug CandidateVANCOUVER, BC / ACCESS Newswire / October 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce two major development milestones for BNT23001, its proprietary sublingual Cladribine oral dissolvable film ("ODF") drug candidate for the treatment of relapsing forms of multiple sclerosis ("MS"). The Company has completed Good Manufacturing Practice ("GMP") manufacturing of approximately 1,500 investigational Cladribine films and submitted its Clinical Trial Application ("CTA") through the European Union's Clinical Trials Information System ("CTIS") on October 16, 2026.
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic StudyVANCOUVER, BC / ACCESS Newswire / September 8, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the advancement of its proprietary sublingual Everolimus oral dissolvable film ("ODF") program, initially targeting organ transplantation, with a comparative large-animal pharmacokinetic study.
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical StudiesVANCOUVER, BC / ACCESS Newswire / August 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the completion of the Investigational Medicinal Product Dossier ("IMPD") for BNT23001, the Company's lead proprietary sublingual cladribine oral dissolvable film (ODF) product candidate for the treatment of relapsing forms of multiple sclerosis (MS). Completion of the IMPD represents a significant regulatory milestone and advances BioNxt's lead development program toward its planned first human bioequivalence study.
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery PipelineVANCOUVER, BC / ACCESS Newswire / August 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery PipelineVANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development UnderwayVANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform.
